{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T09:59:46Z","timestamp":1758448786311,"version":"3.44.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.metabol.2011.10.011","type":"journal-article","created":{"date-parts":[[2011,12,28]],"date-time":"2011-12-28T18:36:30Z","timestamp":1325097390000},"page":"787-793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The effect of ziprasidone on body weight and energy expenditure in female rats"],"prefix":"10.1016","volume":"61","author":[{"given":"Subin","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Seon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Churl","family":"Namkoong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Hyeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Pyo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 7","key":"10.1016\/j.metabol.2011.10.011_bb0005","first-page":"22","article-title":"Antipsychotic-induced weight gain: a review of the literature","volume":"62","author":"Allison","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.metabol.2011.10.011_bb0010","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.metabol.2011.10.011_bb0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00004583-200203000-00014","article-title":"Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study","volume":"41","author":"Ratzoni","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.metabol.2011.10.011_bb0020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.metabol.2011.10.011_bb0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0920-9964(02)00305-5","article-title":"Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol","volume":"60","author":"Atmaca","year":"2003","journal-title":"Schizophr Res"},{"key":"10.1016\/j.metabol.2011.10.011_bb0030","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4088\/JCP.v62n0404","article-title":"Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone","volume":"62","author":"Basson","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.metabol.2011.10.011_bb0035","first-page":"102","article-title":"Weight changes during treatment with phenothiazine derivatives","volume":"2","author":"Klett","year":"1960","journal-title":"J Neuropsychiatr"},{"key":"10.1016\/j.metabol.2011.10.011_bb0040","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","article-title":"Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group","volume":"156","author":"Tohen","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.metabol.2011.10.011_bb0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1192\/bjp.174.1.15","article-title":"Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy","volume":"174","author":"Tran","year":"1999","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.metabol.2011.10.011_bb0050","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2165\/00002018-200225150-00005","article-title":"Glucose intolerance with atypical antipsychotics","volume":"25","author":"Hedenmalm","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.metabol.2011.10.011_bb0055","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4088\/JCP.v59n0604","article-title":"Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications","volume":"59","author":"Hagg","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.metabol.2011.10.011_bb0060","doi-asserted-by":"crossref","first-page":"369","DOI":"10.4088\/JCP.v63n0415f","article-title":"Sleep apnea associated with antipsychotic-induced obesity","volume":"63","author":"Wirshing","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.metabol.2011.10.011_bb0065","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004850-200209000-00001","article-title":"A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg\/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study","volume":"17","author":"Arato","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.metabol.2011.10.011_bb0070","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4088\/JCP.v62n0507","article-title":"The apparent effects of ziprasidone on plasma lipids and glucose","volume":"62","author":"Kingsbury","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.metabol.2011.10.011_bb0075","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.pnpbp.2007.06.008","article-title":"Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial","volume":"31","author":"Ratner","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.metabol.2011.10.011_bb0080","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eurpsy.2006.06.004","article-title":"Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial","volume":"22","author":"Kudla","year":"2007","journal-title":"Eur Psychiatry"},{"issue":"Suppl 19","key":"10.1016\/j.metabol.2011.10.011_bb0085","first-page":"40","article-title":"Tolerability of ziprasidone: an expanding perspective","volume":"64","author":"Daniel","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.metabol.2011.10.011_bb0090","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/10673220701679838","article-title":"The CATIE schizophrenia trial: results, impact, controversy","volume":"15","author":"Manschreck","year":"2007","journal-title":"Harv Rev Psychiatry"},{"key":"10.1016\/j.metabol.2011.10.011_bb0095","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/WNF.0b013e3181d52b85","article-title":"Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia","volume":"33","author":"Kim","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.metabol.2011.10.011_bb0100","first-page":"CD006627","article-title":"Ziprasidone versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.metabol.2011.10.011_bb0105","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/1389450043490514","article-title":"Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics","volume":"5","author":"Baptista","year":"2004","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.metabol.2011.10.011_bb0110","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1038\/sj.npp.1300291","article-title":"H(1)-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Goudie","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.metabol.2011.10.011_bb0115","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-2999(01)01188-8","article-title":"Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile","volume":"425","author":"Schmidt","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.metabol.2011.10.011_bb0120","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.metabol.2011.10.011_bb0125","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/026988110401800303","article-title":"Receptor mechanisms in the treatment of schizophrenia","volume":"18","author":"Reynolds","year":"2004","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.metabol.2011.10.011_bb0130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2337\/diabetes.52.2.315","article-title":"Hyperactivity and reduced energy cost of physical activity in serotonin 5-HT(2C) receptor mutant mice","volume":"52","author":"Nonogaki","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2011.10.011_bb0135","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s002130050952","article-title":"Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice","volume":"143","author":"Vickers","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.metabol.2011.10.011_bb0140","first-page":"121","article-title":"An animal model of antipsychotic-induced weight gain","volume":"152","author":"Arjona","year":"2004","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.metabol.2011.10.011_bb0145","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0006-8993(02)03616-8","article-title":"Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance","volume":"957","author":"Baptista","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.metabol.2011.10.011_bb0150","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/0269881106069637","article-title":"Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities","volume":"21","author":"Cooper","year":"2007","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.metabol.2011.10.011_bb0155","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/026988110201600402","article-title":"Characterization of olanzapine-induced weight gain in rats","volume":"16","author":"Goudie","year":"2002","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.metabol.2011.10.011_bb0160","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ejphar.2004.10.015","article-title":"Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat","volume":"505","author":"Kirk","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.metabol.2011.10.011_bb0165","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bbr.2005.05.004","article-title":"Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection","volume":"163","author":"Minet-Ringuet","year":"2005","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.metabol.2011.10.011_bb0170","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.appet.2006.01.008","article-title":"Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration","volume":"46","author":"Minet-Ringuet","year":"2006","journal-title":"Appetite"},{"key":"10.1016\/j.metabol.2011.10.011_bb0175","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/026988110201600111","article-title":"The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study","volume":"16","author":"Thornton-Jones","year":"2002","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.metabol.2011.10.011_bb0180","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.bbr.2004.12.015","article-title":"Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats","volume":"160","author":"Fell","year":"2005","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.metabol.2011.10.011_bb0185","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.euroneuro.2003.12.001","article-title":"Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats","volume":"14","author":"Fell","year":"2004","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.metabol.2011.10.011_bb0190","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/0269881104042613","article-title":"Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats","volume":"18","author":"Fell","year":"2004","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.metabol.2011.10.011_bb0195","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00213-007-0833-9","article-title":"The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats","volume":"194","author":"Fell","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.metabol.2011.10.011_bb0200","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.bbr.2010.08.046","article-title":"Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone","volume":"216","author":"Shobo","year":"2011","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.metabol.2011.10.011_bb0205","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1590\/S1807-59322010000900012","article-title":"The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats","volume":"65","author":"von Wilmsdorff","year":"2010","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.metabol.2011.10.011_bb0210","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881107081519","article-title":"Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats","volume":"22","author":"Snigdha","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.metabol.2011.10.011_bb0215","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.physbeh.2008.11.011","article-title":"Risperidone alters food intake, core body temperature, and locomotor activity in mice","volume":"96","author":"Cope","year":"2009","journal-title":"Physiol Behav"},{"key":"10.1016\/j.metabol.2011.10.011_bb0220","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/JCP.0b013e3181bfe13e","article-title":"30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice","volume":"29","author":"Coccurello","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.metabol.2011.10.011_bb0225","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00213-006-0368-5","article-title":"Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects","volume":"186","author":"Coccurello","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.metabol.2011.10.011_bb0230","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/oby.2010.17","article-title":"Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625","volume":"18","author":"Liebig","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.metabol.2011.10.011_bb0235","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J"},{"year":"2002","series-title":"Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers","author":"Research CfDEa","key":"10.1016\/j.metabol.2011.10.011_bb0240"},{"key":"10.1016\/j.metabol.2011.10.011_bb0245","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jpsychires.2006.01.011","article-title":"Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain","volume":"41","author":"Pillai","year":"2007","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.metabol.2011.10.011_bb0250","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881103017001700","article-title":"The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat","volume":"17","author":"Abdul-Monim","year":"2003","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.metabol.2011.10.011_bb0255","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00023210-200721110-00004","article-title":"Adverse effects of atypical antipsychotics : differential risk and clinical implications","volume":"21","author":"Haddad","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.metabol.2011.10.011_bb0260","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0149-2918(02)85003-2","article-title":"Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia","volume":"24","author":"Stimmel","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.metabol.2011.10.011_bb0265","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1527-3458.2007.00008.x","article-title":"Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials","volume":"13","author":"Greenberg","year":"2007","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.metabol.2011.10.011_bb0270","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1176\/appi.ajp.159.6.1055","article-title":"Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine","volume":"159","author":"Gothelf","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.metabol.2011.10.011_bb0275","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/appi.ajp.162.1.118","article-title":"Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis","volume":"162","author":"Graham","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.metabol.2011.10.011_bb0280","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/oby.2010.6","article-title":"Increased food intake and energy expenditure following administration of olanzapine to healthy men","volume":"18","author":"Fountaine","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.metabol.2011.10.011_bb0285","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1055\/s-2002-31521","article-title":"Decrease of energy expenditure causes weight increase in olanzapine treatment\u2014a case study","volume":"35","author":"Virkkunen","year":"2002","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.metabol.2011.10.011_bb0290","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/35007527","article-title":"Towards a molecular understanding of adaptive thermogenesis","volume":"404","author":"Lowell","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2011.10.011_bb0295","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0005-2728(00)00247-4","article-title":"UCP1: the only protein able to mediate adaptive non-shivering thermogenesis and metabolic inefficiency","volume":"1504","author":"Nedergaard","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.metabol.2011.10.011_bb0300","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.brainres.2005.05.045","article-title":"Orexin A in the nucleus accumbens stimulates feeding and locomotor activity","volume":"1050","author":"Thorpe","year":"2005","journal-title":"Brain Res"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049511003507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049511003507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T03:57:23Z","timestamp":1758427043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049511003507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0026049511003507"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2011.10.011","relation":{},"ISSN":["0026-0495"],"issn-type":[{"type":"print","value":"0026-0495"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of ziprasidone on body weight and energy expenditure in female rats","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2011.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2012 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}